Statin therapy is associated with aneurysm sac regression after endovascular aortic repair
Journal of Vascular Surgery, 04/03/2012
Raux M et al. – This study showed that statin use was predictive of sac regression after endovascular aneurysm repair (EVAR) with the Zenith graft device. This effect needs to be confirmed by larger randomized trials or by large population evaluation.Methods
- This monocentric retrospective study included patients with abdominal aortic aneurysms treated by EVAR using the Zenith (Cook, Bloomington, Ind) graft device.
- Authors excluded patients presenting with perioperative sac enlargement factors such as endoleaks, endotension, infectious, inflammatory, ruptured, or anastomotic aneurysms.
- Authors prospectively assessed standard clinical and anatomic data, as well as statin use, at the time of EVAR and during follow–up.
- The primary end point was the decrease in the largest transverse aortic diameter at 24 months compared with the preoperative diameter.
- Among 166 patients treated by a Zenith device and meeting the inclusion criteria, 120 were identified as statin users and 46 as nonstatin users, with comparable characteristics.
- At 24 months of follow–up, statin group patients had a greater aneurysm sac reduction (25% vs 14%; P < .0001).
- At a threshold of 5 mm in diameter regression, statin use was a positive factor of retraction (odds ratio, 7.93; 95% confidence interval, 3.22–15.52; P < .0001).
- Multivariate analysis revealed statin use was an independent predictive factor of sac regression (adjusted odds ratio, 9.39; 95% confidence interval, 3.45–25.56).